Interval between prior SARS-CoV-2 infection and booster vaccination impacts magnitude and quality of antibody and B cell responses
Authors:
- 27 September 2022
- Vol. 185 (23) , 4333-4346.e14
Abstract
No abstract availableKeywords
All Related Versions
Funding Information
- National Institutes of Health
- National Institute of Allergy and Infectious Diseases
- Division of Intramural Research
- Vaccine Research Center
This publication has 38 references indexed in Scilit:
- Efficient recall of Omicron-reactive B cell memory after a third dose of SARS-CoV-2 mRNA vaccineCell, 2022
- mRNA-1273 or mRNA-Omicron boost in vaccinated macaques elicits similar B cell expansion, neutralizing responses, and protection from OmicronCell, 2022
- Imprinted SARS-CoV-2-specific memory lymphocytes define hybrid immunityCell, 2022
- Immunogenicity of standard and extended dosing intervals of BNT162b2 mRNA vaccineCell, 2021
- COVID-19 vaccine mRNA-1273 elicits a protective immune profile in mice that is not associated with vaccine-enhanced disease upon SARS-CoV-2 challengeImmunity, 2021
- Adaptive immunity to SARS-CoV-2 and COVID-19Cell, 2021
- An Integrated Multi-omic Single-Cell Atlas of Human B Cell IdentityImmunity, 2020
- Restricted Clonality and Limited Germinal Center Reentry Characterize Memory B Cell Reactivation by BoostingCell, 2020
- Activation Dynamics and Immunoglobulin Evolution of Pre-existing and Newly Generated Human Memory B cell Responses to Influenza HemagglutininImmunity, 2019
- Distinct Effector B Cells Induced by Unregulated Toll-like Receptor 7 Contribute to Pathogenic Responses in Systemic Lupus ErythematosusImmunity, 2018